国产多西他赛为主的联合化疗治疗转移性乳腺癌

 目的 观察国产多西他赛为主的联合化疗治疗转移性乳腺癌的疗效、毒副反应和临床受益反应（Clinical　benefit　response，CBR），并以进口多西他赛作对照。方法 A组30例转移性乳腺癌患者，既往未采用蒽环类药物治疗的14例采用国产多西他赛联合阿霉素治疗（A1组），既往蒽环类药物治疗失败的16例采用国产多西他赛联合卡培他滨治疗（A2组）；B组25例转移性乳腺癌患者作对照，其中未采用蒽环类药物治疗的11例采用进口多西他赛联合阿霉素治疗（BI组），既往蒽环类药物治疗失败的14例采用进口多西他赛联合卡培他滨治疗（B2组）；3周为1个周期，2周期评价疗效，记录毒副反应。结果 A组有效率（CR＋PR）66．7％，肿瘤控制率（CR＋PR＋SD）93．3％。毒副反应主要为骨髓抑制和脱发，可耐受，无治疗相关性死亡。CBR评价有效者73．3％；B组有效率68％，肿瘤控制率92％。毒副反应与A组相似。CBR评价有效者72％。结论 国产多西他赛为主的联合化疗治疗转移性乳腺癌有较好的疗效，毒副反应可耐受，临床受益反应良好，与进口多西他赛的疗效和不良反应相似。

Domestic Docetaxel-based Combination Chemotherapy in Treatment of Metastatic Breast Cancer

Objective With taxotere as a control,to evaluate the efficacy,toxicity and CBR of domestic docetaxel-based combination chemotherapy in the treatment of metastatic breast cancer.Methods Fourteen metastatic breast cancer patients without anthracycline-pretreated were treated with docetaxel and doxorubicin(A1)and sixteen metastatic breast cancer patients with anthracycline-pretreated were treated with docetaxel and capecitabine(A2).Eleven metastatic breast cancer patients without anthracycline-pretreated were treated with taxotere and doxorubicin (B1) and fourteen metastatic breast cancer patients with anthracycline-pretreated were treated with taxotere and capecitabine(B2).Every 3 weeks a cycle.Efficacy,toxicity and CBR were recorded in every 2 cycles.Results Fifty-five patients were evaluated.The response rate was 66.7% and 68%.The tumor control rate was 93.3% and 92%.The main toxicities were bone marrow suppression and alopecia,and were tolerable.The CBR was 73.3% and 72%.There was no significant difference between treated group and control group.Conclusion Domestic docetaxel-based combination chemotherapy is effective for metastatic breast cancer.It is well-tolerated and well-clinical benefit responsed.